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Abstract 23	  
An adverse intra-uterine environment, induced by maternal consumption of diets high in saturated fat 24	  
or low in protein have been implicated as a potential trigger for development of metabolic disease in 25	  
later life. However, the underlying mechanisms responsible for this programming of obesity have yet 26	  
to be described. Recent studies have demonstrated that interferon regulatory factors 3 (IRF3) and 4 27	  
(IRF4) function to repress adipogenesis. We investigated whether impaired IRF3 and IRF4 function 28	  
may predispose to development of metabolic disease in a model of programmed obesity. Changes in 29	  
IRF3 and IRF4 levels, adipogenic gene expression and adiponectin signalling were measured in white 30	  
adipose tissue from programmed male offspring of rat dams fed a low-protein diet (MLP), which are 31	  
predisposed to obesity. 3T3L1 adipocytes were used to determine novel regulatory mechanisms 32	  
governing IRF expression. 33	  
IRF3 and IRF4 levels were suppressed in MLP rats, together with raised lipogenic and adipogenic 34	  
gene expression. Adiponectin and adiponectin receptor 1 and 2 mRNA levels were reduced in MLP 35	  
rats, along with levels of PPAR  and activity of AMPK, two downstream targets of adiponectin. 36	  
Further studies determined that both IRF3 and IRF4 are induced by adiponectin, with adiponectin-37	  
AMPK and adiponectin-PPAR  signalling regulating IRF3 and IRF4, respectively. 38	  
We demonstrate that impaired ability to repress adipogenesis and lipogenesis, through dysregulated 39	  
adiponectin-PPAR -AMPK-IRF signalling, may play a causal role in predisposing MLP offspring to 40	  
development of obesity and metabolic disease in later life. 41	  
 42	  
Introduction 43	  
An adverse intra-uterine environment has also been implicated as a potential trigger for 44	  
development of obesity in later life (1-3).  Examples of poor maternal nutrition include maternal 45	  
consumption of diets high in saturated fat or a diet low in protein diet (1, 4).  Maternal consumption of 46	  
a low protein (Maternal Low Protein; MLP) diet results in offspring with a low birth weight in 47	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humans and animal models (4). Moreover, there exists a strong positive correlation between low 48	  
birth-weight and the development in later life of obesity, insulin resistance and type 2 diabetes (5). 49	  
Epidemiological and experimental evidence suggests that an imbalance between prenatal (e.g. 50	  
maternal protein restriction) and post-natal (e.g. excess dietary carbohydrate) nutrition can predispose 51	  
to development of obesity (1).  In agreement, children exposed to growth-restricted conditions during 52	  
development exhibit increased adiposity in childhood and later life (6), whilst the offspring of rats fed 53	  
a low-protein diet display a greater predisposition to develop obesity and related metabolic disorders 54	  
in response to high-fat feeding compared to controls (1, 5).  This phenomenon, termed the ‘thrifty 55	  
phenotype’, suggests that fetal malnutrition may lead to physiological changes that programme the 56	  
fetus for survival in what it predicts to be a poor nutritional environment.  This evolutionary 57	  
programming is less advantageous when food is abundant, potentially predisposing to obesity (5).  58	  
However, the underlying mechanisms responsible for this programming of obesity have yet to be 59	  
described.  60	  
Recent studies have identified the immunoregulatory proteins, interferon regulatory factors 3 and 4 61	  
(IRF3 and IRF4) as key regulators of adipocyte function (7, 8).  IRF4 increases during adipocyte 62	  
differentiation and functions to repress adipogenesis and lipogenesis and induce lipolysis in white 63	  
adipose tissue. IRF4 expression is repressed by insulin, and consequently IRF4 levels are reduced in 64	  
insulin resistant mouse models, as well as being elevated during fasting and reduced during re-65	  
feeding. Adipocytes lacking IRF4 display increased expression of lipogenic genes including fatty acid 66	  
synthase (FAS; gene code: Fasn) and sterol regulatory-element binding-protein 1 (SREBP1).  67	  
Moreover, IRF4 knockout mice have larger adipocytes, are obese and develop T2DM. Less is known 68	  
about the regulation of IRF3 (7, 8). 69	  
To further examine the early life mechanistic changes following exposure to an adverse intra-uterine 70	  
environment responsible for onset of obesity and metabolic syndrome in later-life, we examined the 71	  
role of IRF3 and IRF4 in the MLP model of fetal programming. Further to this, we investigated novel 72	  
mechanisms involved in regulation of IRF3 and IRF4 in adipocytes and white adipose tissue. 73	  
Materials and Methods 74	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Experimental Animals 75	  
Studies were conducted in adherence to the regulations of the U.K. Animal Scientific Procedures Act 76	  
(1986), under project license PPL 70/7276. All animals were maintained on a 12 h light/12 h dark 77	  
cycle (light from 07:00).  All experiments were conducted in the fed state, unless stated otherwise. 78	  
Animals were sacrificed under CO2 asphyxiation.  79	  
Maternal Low Protein Model 80	  
Pregnant female Wistar rats (250 – 300 g; Charles River, Kent, UK) were randomly assigned to either 81	  
control (CON; 20% protein) or an isocaloric maternal low protein (MLP; 8%) diets (Hope Farms BV, 82	  
Woerden, Netherlands) and maintained on the respective diet throughout pregnancy and lactation (12 83	  
rats/group).  Pregnant dams fed the low-protein diet did not exhibit any differences in caloric intake 84	  
compared to controls.  Despite this, MLP offspring weighed significantly less at 3 days of age than 85	  
CON offspring (28%; P<0.05).  Male offspring were weaned at 24 days and maintained on standard 86	  
rodent diet thereafter.  CON and MLP offspring were killed at 8 weeks and visceral WAT depots were 87	  
snap-frozen for analysis, whilst blood was collected for measurement of glucose and insulin.    88	  
PPARα-/- Mice 89	  
Male PPARα-/- mice, bred onto a SV/129 genetic background, were provided by Drs. J. Peters and 90	  
F.J. Gonzalez (National Institutes of Health, Bethesda, MD). Wild-type SV/129 mice (from Charles 91	  
River, UK) were used as controls. 92	  
 93	  
Metformin treatment 94	  
Eight-week old male C57Bl/6 mice (Charles River, Kent, UK) maintained on standard rodent diet 95	  
were administered metformin (250 mg/kg/day) or an equal volume of water daily for seven days by 96	  
oral gavage. 97	  
 98	  
3T3L1 Culture and Differentiation 99	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3T3-L1 preadipocytes were cultured (37ºC; 5% CO2) in Dulbecco’s Modified Eagle Media (DMEM; 100	  
25 mM glucose) supplemented with 10% bovine calf serum (BCS), (both Sigma Aldrich, Poole, UK) 101	  
until confluent. Two days post-confluence (Differentiation day 0), to induce differentiation media was 102	  
changed and replaced with DMEM/10% foetal calf serum (FCS) supplemented with insulin (1 µg/ml), 103	  
dexamethasone (0.25 mM) and isobutyl-1-methylxanthine IBMX (0.5 mM).  After 2 days 104	  
(differentiation day 2), media was replaced with DMEM/10% FCS supplemented with insulin (1 105	  
µg/ml). After 4 days (differentiation day 4) media was replaced with DMEM/10% FCS. All media 106	  
contained 100 U/ml penicillin and 100 µg/ml streptomycin (both Sigma Aldrich, Poole, UK). 107	  
Differentiation of pre-adipocytes to adipocytes was confirmed by measurement of PPARγ gene 108	  
expression. Treatments, carried out on differentiation day 8, were as follows; adiponectin (30 µg/ml), 109	  
WY-14643 (10 µM) for 24 h. All treatments were carried out in DMEM containing 10% FCS.  110	  
Immunoblotting 111	  
Solubilized protein samples (10 µg; measured and equalized in each fraction using an RC-DC BioRad 112	  
system (BioRad, UK)) were separated by SDS-PAGE and transferred onto PDVF membrane (GE 113	  
Healthcare, Amersham, UK).  Blots were blocked with 5% (w/v) bovine serum albumin (BSA) or 5% 114	  
milk in Tris-buffered saline/0.1% Tween-20 (TBS/T) solution and then incubated overnight in 115	  
primary antibody.  Antibodies used in this study are anti-phospho(Thr172)AMPK, anti-AMPK, anti-116	  
phospho(Ser171)ACC and anti-ACC (Cell Signaling Technologies, MA, USA). Detection of bands was 117	  
achieved by using the chemiluminescence substrate SuperSignal West Pico (Pierce, Rockford, IL, 118	  
USA). Reference protein measurements were made with mouse monoclonal anti-β-actin (clone AC-119	  
15; Sigma, Poole, UK) primary antibody in a 3% (w/v) milk-TBS/T solution, at 4ºC. 120	  
 121	  
Quantitative RT-PCR 122	  
Gene expression was measured by qRT-PCR, using Taqman® or Sybr green® methodology.  Gene 123	  
expression was determined by ∆∆Ct methodology, normalised against 18S ribosomal RNA (Applied 124	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Biosystems, UK). Changes in gene expression are represented as fold change relative to one, where 125	  
control equals one. All primer and probes are from Eurogentec, UK. A list of primers can be found in 126	  
supplemental table 1 (supporting data). 127	  
Serum Insulin and Glucose 128	  
Insulin was analysed by ELISA (Mercodia, Uppsala, Sweden) using rat insulin as standard.  Plasma 129	  
glucose was measured by a glucose oxidase/peroxidase method (Roche Diagnostics, Lewes, U.K.).   130	  
Statistical analysis  131	  
Results are expressed as mean ± SEM.  Statistical comparisons were obtained using GraphPad 132	  
(GraphPad Software, CA, USA).  Statistical differences were calculated using an unpaired t-test. 133	  
Results 134	  
 135	  
Metabolic data for MLP offspring 136	  
Pregnant dams fed a low-protein diet did not exhibit any differences in food intake compared to 137	  
controls (data not shown).  Despite this MLP offspring weighed significantly less at 3 days of age 138	  
than control litter mates (28%; p<0.05).  After 8-weeks consumption of standard rodent diet, MLP 139	  
offspring displayed modest but insignificant increases in fasting insulin (16.0 ± 3.2 µU/ml) compared 140	  
to controls (14.4 ± 1.3 µU/ml) (p=0.65).  Additionally, fasting plasma glucose levels were mildly but 141	  
not significantly increased in MLP offspring (4.36 ± 0.13 mmol/l) compared to control (4.11 ± 0.21 142	  
mmol/l) (p=0.33), whilst glucose area under the curve (AUC) analysis for glucose tolerance tests 143	  
resulted in a modest increased AUC values for MLP (9.76 ± 1.29 mmol/L/min) compared to control 144	  
(7.45 ± 0.79 mmol/L/min) (p=0.16) (Table 1). 145	  
 146	  
MLP offspring display altered adipogenic and lipogenic gene expression 147	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Whilst no significant changes in metabolic data were observed at this early stage in the MLP rats, it is 148	  
possible that mechanistic changes may occur during this early-life period which would predispose to 149	  
later development of metabolic disease. Therefore, by focussing on altered lipogenesis and 150	  
adipogenesis in white adipose tissue, we next attempted to identify early-life metabolic changes which 151	  
would likely lead to onset of the established later-life metabolic defects induced by MLP.  IRF3 and 152	  
IRF4 are recently identified repressors of adipogenesis and lipogenesis (7, 8). Gene expression of 153	  
IRF3 and IRF4 was markedly reduced in white adipose tissue of MLP rats compared to controls 154	  
(Figure 1a and 1b). These changes occurred in parallel with increased mRNA expression of 155	  
SREBP1c, elevated mRNA and protein levels of FASN as well as increased ACC protein (Figure 1c – 156	  
e), consistent with a role for IRF4 in repressing transcription of these genes. This data implies that 157	  
early life changes in IRF3 and IRF4 occur in MLP rats and may contribute to increased risk of 158	  
development of obesity and metabolic syndrome in later life.  159	  
 160	  
IRF3 and IRF4 suppression is associated with impaired adiponectin signalling.  161	  
Previous studies have demonstrated that insulin exerts regulatory control of IRF4, whilst less is 162	  
known about IRF3 regulation in the context of obesity and metabolic syndrome. Insulin was reported 163	  
to repress IRF4 expression in vitro in adipocytes and in vivo under fed conditions, and in obese, 164	  
hyperinsulinaemic rodent models (7). However, despite marked reductions in IRF3 and IRF4 165	  
expression, we did not observe significant changes in serum insulin levels in our models (Table 1). 166	  
This suggested the existence of an alternative regulatory mechanism controlling IRF4, and potentially 167	  
IRF3, in white adipose tissue.  Adipokines, such as adiponectin, are bioactive peptides secreted from 168	  
adipose tissue which exert metabolic control over a number of insulin sensitive tissue, including, in an 169	  
autocrine manner, adipose tissue. We next investigated potential alterations in adiponectin signalling 170	  
in MLP rats, with aim of determining alternative mechanisms of IRF3 and IRF4 regulation. 171	  
Remarkably, we found that mRNA levels of adiponectin (ADIPOq; Figure 2a) and adiponectin 172	  
receptor 1 (AdipoR1) and receptor 2 (AdipoR2) were dramatically suppressed in MLP rats by ≈90% 173	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relative to control (Figure 2b – c), suggesting that impaired adiponectin signalling may lead to 174	  
decreased IRF3 and IRF4 expression.  To investigate this further, we used the 3T3L1 adipocyte cell 175	  
line. Consistent with impaired adiponectin signalling and reduced IRF expression in the white adipose 176	  
tissue of MLP rats, incubation of 3T3L1 adipocytes with adiponectin led to increased mRNA levels of 177	  
IRF3 and IRF4 (Figure 2d – e). This suggests that, in addition to insulin, adiponectin provides an 178	  
additional level of regulatory control over IRF3 and IRF4 in white adipose tissue.  179	  
Adiponectin regulates IRF3 and IRF4 through AMPK and PPARα 180	  
Adiponectin, via signalling through adiponectin receptor 1 (AdipoR1) and receptor 2 (AdipoR2) has 181	  
been reported to exert metabolic effects through activation of the energy sensing enzyme AMP-182	  
activated protein kinase (AMPK) and the nuclear receptor peroxisome-proliferator activated receptor 183	  
α (PPARα) (9)].  Both AMPK and PPARα play important roles in regulating lipogenesis and fatty 184	  
acid oxidation (9-11). Consistent with observed reductions in adiponectin and AdipoR1 expression, 185	  
MLP rats also displayed decreased protein levels of phospho(Thr172)-AMPK (Figure 3a).  Since 186	  
phosphorylation at Thr172 leads to AMPK activation, this observation suggests reduced AMPK 187	  
activity in MLP rats.  In addition, protein levels of phospho(Ser79)-ACC, a downstream target of 188	  
AMPK, were also reduced in MLP offspring compared to control (Figure 3a).  Total protein levels of 189	  
AMPK were unchanged, demonstrating that decreased AMPK activation did not occur because of 190	  
MLP-induced reductions in total protein. In contrast, total-ACC protein levels were elevated in MLP 191	  
mice, reflecting increased lipogenesis, changes that are consistent with increased lipogenic gene 192	  
expression (Figure 1e). Furthermore, reflecting decreased AdipoR2 expression, we also observed 193	  
decreased mRNA levels of PPARα in MLP rats, compared to control (Figure 3b). Transcriptional 194	  
modulation by PPARα requires the presence of the co-activator PPARγ co-activator 1α (PGC1α). 195	  
Consistent with this, PGC1α mRNA levels were also suppressed in MLP rat adipose tissue (Figure 196	  
3c). 197	  
To further analyse the potential role of adiponectin-AMPK-PPARα signalling in regulating IRF3 and 198	  
IRF4 expression, we initially used 3T3L1 adipocytes. Use of 3T3L1 adipocytes allowed for specific 199	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examination of IRF4 regulation in a model lacking macrophages, which may influence results given 200	  
the role of IRF4 in immune regulation (12). Adipocyte differentiation was confirmed by measurement 201	  
of mRNA levels of PPARγ (data not shown). Treatment of differentiated adipocytes with WY14643, a 202	  
potent PPARα agonist, had no effect on IRF3 mRNA (Figure 4a) but did induce expression of IRF4 203	  
(Figure 4b). We further analysed these putative signalling mechanism using PPARα knockout mice, 204	  
which displayed ≈90% reduction in PPARα mRNA levels in white adipose tissue, together with a 205	  
marked reduction in PGC1α mRNA levels (Figure 4c – d). Significantly, in PPARα knockout mice 206	  
the normal IRF4 responses to fasting and feeding were disrupted (Figure 4e). Consistent with previous 207	  
reports (7) IRF4 levels were induced by fasting in wild-type mice. However, this effect was blunted in 208	  
PPARα knockout mice, where IRF4 levels were reduced in fasted compared to fed mice. Similar to 209	  
MLP rats, PPARα knockout mice also displayed reduced IRF4 levels (Figure 4f), together with raised 210	  
levels of ACC and SREBP1c (Figure 4g – h), indicative of elevate lipogenesis and adipogenesis in 211	  
white adipose tissue. Taken together, these results indicate that an adiponectin-PPARα signalling 212	  
pathway induces IRF4 mRNA expression in white adipose tissue. Moreover, this pathway is 213	  
dysregulated in response MLP, and this may in part mediate the metabolic defects associated with this 214	  
MLP. 215	  
Adiponectin-AMPK signalling may regulate IRF3. 216	  
In contrast to IRF4, IRF3 was unaffected by PPARα agonist in vitro, indicating an alternative 217	  
regulatory mechanism for IRF3 (Figure 4a). Since adiponectin induced both IRF3 and IRF4, but 218	  
PPARα regulated IRF4 only, we reasoned that AMPK, another target of adiponectin, may exert 219	  
regulatory control over IRF3. To test this, we used metformin, as a known activator of AMPK (13)], 220	  
rather than for its actions as an anti-diabetic treatment. Administration of metformin to control mice 221	  
led to significant induction of IRF3 (Figure 5a) but had no effect on IRF4 mRNA levels (Figure 5b), 222	  
implying that adiponectin-AMPK signalling selectively induces IRF3 in white adipose tissue. 223	  
Discussion 224	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We report here that expression of IRF3 and IRF4, two key repressors of adipogenesis, are reduced in 225	  
offspring of rats fed a protein-restricted diet during pregnancy and lactation, in parallel with mildly 226	  
elevated fasting insulin and glucose.  Human epidemiological studies have consistently reported that 227	  
exposure to an adverse intrauterine environment, such as protein-restriction, leads to an increased risk 228	  
of development of obesity, T2DM and cardiovascular disease in later life (3, 5, 6). Experimental 229	  
model studies have reported that MLP offspring gain more weight, have increased susceptibility to 230	  
development on metabolic syndrome and display impaired adipocyte function when placed a high fat 231	  
diet (1, 14, 15). However the underlying regulatory mechanisms driving these processes are yet to be 232	  
fully elucidated. Our data provides evidence that a loss of ability to efficiently repress adipogenesis 233	  
and lipogenesis, as a result of marked early-life reductions in IRF3 and IRF4, may contribute to 234	  
impaired adipocyte function and increased risk of obesity in later life. Whilst metabolic changes 235	  
observed in this model are mild, the early life mechanistic changes reported here would likely make a 236	  
key contribution to the expected, and previously reported, metabolic deterioration likely observed in 237	  
these animals in later life.  238	  
Previous studies have described that IRF4 expression and function is suppressed by insulin, and that 239	  
as a result, IRF4 expression is lower in white adipose tissue depots obtained from rodent models 240	  
characterised by insulin resistance; HFD, ob/ob and db/db mice (7). Despite this well characterised 241	  
role of insulin, our MLP model displayed a marked reduction in IRF3 and IRF4, without significant 242	  
changes in serum insulin. Instead, our data point the involvement of the adiponectin-PPARα and 243	  
adiponectin-AMPK signalling pathways in the regulation of IRF4 and IRF3 respectively. Adiponectin 244	  
is a bioactive adipokine expressed at high levels and secreted from adipose tissue (16). Adiponectin 245	  
exerts metabolic regulatory effects via autocrine, paracrine and endocrine function, through the 246	  
receptors adipoR1 and adipoR2, which in turn activate AMPK and PPARα (9, 16). Conversely, 247	  
PPARα agonists have been reported to upregulate adiponectin and AdipoR1 and AdipoR2, whilst 248	  
adiponectin is suppressed in PPARα knockout mice (17). PPARα is a transcription factor for genes 249	  
involved in lipolysis and fatty acid oxidation and PPARα null mice maintained on a high-fat diet 250	  
become more obese than wild type (18). Despite suppression of insulin levels and increases in FA 251	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supply, PPARα-deficient mice exhibit an impaired ability to adequately up-regulate hepatic FA 252	  
oxidation in response to fasting [18]. Insulin resistance induced by excess of non-esterified FA and 253	  
circulating TAG can be corrected by the administration of PPARα activators by actions to promote 254	  
removal of intracellular lipid through tissue FA oxidation [19]. PPARα is activated under calorie 255	  
restriction, increasing the expression of genes encoding mitochondrial FA oxidation enzymes, thereby 256	  
increasing the capacity for FA oxidation and intracellular lipid clearance [20]. AMPK activation 257	  
occurs in response to a rise in AMP associated with metabolic stresses that interfere with ATP 258	  
production (e.g., hypoxia or calorie restriction/glucose deprivation) or accelerated ATP consumption 259	  
(e.g., muscle contraction), so as to preserve or maintain tissue function [21]. Therefore, AMPK also 260	  
plays an important role in regulating lipid homeostasis in adipose tissue, having been shown to inhibit 261	  
lipogenesis and during the longer-term increase lipolysis (10). The fact that PPARα levels and other 262	  
oxidation genes (PGC-1α) and proteins (AMPK) are suppressed in MLP rats, while lipogenic genes 263	  
are enhanced (SREBP-1c and FAS), suggest that these mice may develop a similar phenotype to 264	  
PPARα-/- mice, and that the MLP phenotype may be a direct result of reduced PPARα levelsleadin to 265	  
increased IRF4 levels. Under both conditions, fatty acid oxidation is decreased and lipogenesis is 266	  
enhanced, again potential involving an IRF-mediated mechanism. Several mechanisms for these 267	  
actions of AMPK and PPARα have been described. Our data suggests a further mechanism of action, 268	  
namely via induction of IRF3 and IRF4, and consequent repression of lipogenesis and induction of 269	  
lipolysis in white adipose tissue. These changes were in turn regulated by adiponectin, and these 270	  
signalling pathways were all impaired in MLP rats.  271	  
In addition to specific effects on lipolysis and lipogenesis, low levels of IRF4 may also reflect poorly 272	  
differentiated adipocytes, since IRF4 is expressed only in fully differentiated adipocytes. Poorly 273	  
differentiated adipocytes are often present in obesity and can lead to hypoxia, inflammation and an 274	  
altered adipokine profile, including lower adiponectin levels (19). Dysregulation of these processes 275	  
are linked to onset of T2DM. Moreover, reduced adiponectin levels occurring as a result of poor 276	  
differentiation, may represent an initial cause of the impaired adiponectin signalling observed in MLP 277	  
mice. Alternatively, this mechanism of impaired adiponectin signalling may induce a feed-forward 278	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loop, with further reductions in adiponectin signalling and consequent worsening of the MLP 279	  
phenotype. In addition, whilst adiponectin has been reported to induce PPARα, the reverse has also 280	  
been documented, with adiponectin upregulated by PPARα agonists and suppressed in white adipose 281	  
tissue of PPARα knockout mice (17). Thus, suppressed PPARα levels in MLP mice may contribute to 282	  
further impairment of adiponectin signalling and consequent exacerbation of the MLP phenotype. 283	  
Further studies are required to determine the exact mechanistic interactions by which PPARα 284	  
regulates IRF4.  285	  
In addition to an established role in adipocytes, IRFs are present in macrophages and infiltrating 286	  
lymphocytes. IRF4 is essential for the function and homeostasis of both mature B and mature T 287	  
lymphocytes. IRF4-deficient mice exhibited a profound reduction in serum immunoglobulin 288	  
concentrations and impaired T lymphocyte function [23]. The altered IRF levels could potentially 289	  
represent reduced immune infiltrate into the white adipose tissue. Further research is needed to clarify 290	  
this. However, given the increased inflammation and macrophage recruitment observed in response to 291	  
reduced adiponectin levels in other studies (16), a reduced immune infiltrate seems unlikely, instead 292	  
suggesting a specific role for adipocyte-IRF3 and IRF4 in this model. 293	  
In summary, we propose that in early life in response to protein restriction  adiponectin signalling is 294	  
impaired leading to reduced activity of PPARα and AMPK, which in turn lead to decreased levels of 295	  
IRF3 and IRF4. This would lead to an inability to repress adipogenesis and lipogenesis, and confer 296	  
increased susceptibility to development of an obese phenotype in later-life.  297	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 Figure Legends 357	  
Figure 1: Reduced IRF levels in white adipose tissue of MLP offspring.  Visceral WAT was 358	  
isolated from 8-week old offspring of MLP and control Wistar rats (n = 6); Gene expression of (A) 359	  
Irf3, (B) Irf4, (C) Srebp1c and (D) Fasn. (E) Protein levels of FASN and ACC.  Western blots are 360	  
representative. Data are expressed as mean ± SEM. * p < 0.05, ** p < 0.01, *** P < 0.001 vs. control. 361	  
Figure 2: Impaired adiponectin signalling in white adipose tissue of MLP offspring leads to 362	  
reduced IRF levels.	  	  Visceral WAT and serum were isolated from 8-week old offspring of MLP and 363	  
control Wistar rats (n = 6); (A) serum insulin levels; mRNA levels of (B) AdipoQ, (C) AdipoR1, and 364	  
(D) AdipoR2 in white adipose tissue. 3T3-L1 adipocytes were treated with adiponectin (30 µg/ml; 24 365	  
h) and mRNA levels of (E) Irf3 and (F) Irf4 were measured by qPCR. Data are expressed as mean ± 366	  
SEM. * p < 0.05, *** p < 0.001 vs. control.	  367	  
FIG. 3. Reduced AMPK and PPARα signalling in white adipose tissue of MLP offspring.  368	  
Visceral WAT was isolated from 8-week old offspring of MLP and control Wistar rats (n = 6); (A) 369	  
protein levels of phospho(Thr.172)-AMPK, total-AMPK and phospho(Ser79)-ACC; mRNA levels of 370	  
(B) Pparα and (C) Pgc1α.Western blots are representative. Data are expressed as mean ± SEM. ** p 371	  
< 0.01, *** p < 0.001 vs. control. 372	  
Figure 4: Adiponectin-PPARα signalling induces IRF4 expression in white adipose tissue. 3T3-373	  
L1 adipocytes were treated with WY14643 (10 µM; 24 h) and mRNA levels of (A) Irf3 and (B) Irf4 374	  
were measured by qPCR. Visceral WAT and serum were isolated from 8-week old PPARα knockout 375	  
and control mice (n = 6); mRNA levels of (C) Pparα (D) Pgc1α, (E – F) Irf4, (G) Srebp1c were 376	  
assessed by qPCR. (H) Protein levels of ACC. Western blots are representative. Data are expressed as 377	  
mean ± SEM. * p < 0.05, **p<0.01, *** p < 0.001 vs. control (FED); ### p<0.001 v. control (FAST). 378	  
15	  
	  
Figure 5: Adiponectin-AMPK signalling may regulate IRF3 expression in white adipose tissue. 379	  
Visceral WAT was isolated from 8-week old C57Bl/6 mice administered metformin (250 mg/kg/day; 380	  
7 days) or saline equivalent (n = 6); mRNA levels of (A) Irf3 and (B) Irf4 were measured by qPCR. 381	  
Data are expressed as mean ± SEM. * p < 0.05, vs. control 382	  
Table 1. Serum insulin and glucose changes between Control and MLP rats 383	  
 384	  
